U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Cr.O4P
Molecular Weight 147.9676
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMIC PHOSPHATE P-32

SMILES

[Cr+3].[O-][32P]([O-])([O-])=O

InChI

InChIKey=IKZBVTPSNGOVRJ-ZYUMTRPDSA-K
InChI=1S/Cr.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3/i;5+1

HIDE SMILES / InChI

Molecular Formula Cr
Molecular Weight 51.9961
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula O4P
Molecular Weight 95.9715
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
PubMed

PubMed

TitleDatePubMed
The use of radioactive phosphorus in the diagnosis of thyroid cancer.
1961 Nov
EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
2007 Aug
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:31:28 GMT 2023
Edited
by admin
on Fri Dec 15 15:31:28 GMT 2023
Record UNII
QHO02LZ4H2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMIC PHOSPHATE P-32
ORANGE BOOK  
Common Name English
CHROMIC PHOSPHATE, P-32
Common Name English
CHROMPHOSPHOTOPE
Brand Name English
CHROMIC PHOSPHATE P 32 [MI]
Common Name English
CHROMIUM(3+) PHOSPHATE-(SUP 32)P (1:1)
Common Name English
CHROMIC PHOSPHATE P 32 [USAN]
Common Name English
CHROMIC PHOSPHATE P32
WHO-DD  
Common Name English
CHROMIC PHOSPHATE P 32
MI   USAN   USP  
USAN  
Official Name English
PHOSPHORIC-(SUP 32)P ACID, CHROMIUM(3+) SALT (1:1)
Common Name English
CHROMIC PHOSPHATE P 32 [USP IMPURITY]
Common Name English
CHROMIC PHOSPHATE,P-32
VANDF  
Common Name English
Chromic phosphate p32 [WHO-DD]
Common Name English
PHOSPHOCOL P32
Brand Name English
PHOSPHOCOL
Common Name English
CHROMIC PHOSPHATE P-32 [ORANGE BOOK]
Common Name English
CHROMIC PHOSPHATE,P-32 [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000205
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
NDF-RT N0000175872
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
NCI_THESAURUS C2124
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
Code System Code Type Description
CAS
24381-60-0
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
RXCUI
121070
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY RxNorm
EVMPD
SUB13361MIG
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
MERCK INDEX
m3501
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY Merck Index
PUBCHEM
71383
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
NCI_THESAURUS
C61676
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
FDA UNII
QHO02LZ4H2
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL2110568
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
SMS_ID
100000086308
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID20947246
Created by admin on Fri Dec 15 15:31:28 GMT 2023 , Edited by admin on Fri Dec 15 15:31:28 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY